Betamethasone drug profile

1. Betamethasone profile
1-Drug name :
*chemical: 9-Fluoro-16beta-methylprednisolone
*Genric name: Betamethasone
*Trade name : (includes routes of administrations and doses)
Brand Name Route of
administration
Dose
lotriderm(cream) Topicl 30g (twice)
Diprosalic(ointment) topical 15g
Daivobet(gel) topical 30g
Celestone(injection) IM 0.2 mL pe square cm
Betnelan oral 0.6mg5mL
Betnovate(lotion) topical 30mL
2-classification(pharmacologic category): Antifungal agent, topical
corticosteroid+systamic.
3-mechanism of action: Betamethasone is a glucocorticoid receptor
agonist. This leads to control the rate of protein synthesis,depresses the
magration of polymorphonu-clear leukocytes, fibroblasts; reverses capillary
peme-abillity and lysosomal stabilization at the cellular level to prevent or
control inflammation. Clotrimazole is antifungal agent that bind to phosphlipids
in the fungal cell membrane altering cell wall permeabillity resulting in loss of
essential intracellular elements, and it becomes active when it is not bound to
transcortin.
4-Indications:
*Topical use (cream, lotion and ointment): for relief of the inflammatory and
pruritic manifestations of corticosteroid-responsive dermatoses, such as
allergic reactions, eczema, and psoriasis
*Topical use (foam): relief of the inflammatory and pruritic manifestations of
corticosteroid-responsive dermatoses of the scalp
*Systemic use: for the treatment of edocrine disorders, rheumatic disorders,
collagen diseases, dermatological diseases, allergic states, ophthalmic
diseases.
5-Pharmacokinetics:
*Administratiom: taking with food (oral)
*half-life:6.5 hours.
*protein binding: 64%
*Distribution: Distributed throughout body tissues; crosses the placenta and
enters the breast milk.
*Metabolism: Hepatic(cyp3A4)
*Excretion: Via urine (<5% as unchanged drug).
*renal clearance:9.5mLmin
Norah fahad alfayez 436019528

2. 6-Side and adverse effect:
• *Topical:
• Skin irritation, redness, rash, itching , or allergic inflammation
of the skin.
• Spread or worsening of untreated infections.
• Thinning of the skin.
• Reduced skin pigmentation.
• telangiectasia.
• Hypertrichosis.
• *oral and IM:
• Abdominal pain and Muscles weakness.
• insomnia,behavioural changes.
• Blurred vision.
• Dizziness, headache and seizures.
7-Dosage Form:
*Topical:base
cream as valerate: Generic :0.1%(15 g, 45 g).
Gel as dipropionate augmented: Generic:0.05% (15 g, 50 g).
Lotion as dipropionat : 0.05% (60 mL).
Ointment as dipropionate: 0.05% (15 g, 45 g).
*systamic:
Solution, Oral: Celestone: 0.6 mg/5 mL
Suspension, Injection: Celestone Soluspan: Betamethasone sodium
phosphate 3 mg and betamethasone acetate 3 mg per 1 mL (5 mL) [contains
benzalkonium chloride, edetate disodium].
8-Contraindications:
*Hypersensititivity to betameth-sone,clotrimazole,other corticosteroids.
*Untreated serious infections.
9-Special Considerations:
*Pregnancy: Category: C
*Lactation: systemically administered corticosteroids enter breast milk and
could suppress growth.
* pediatrics: Use lowest dose (Not recommended for children under 17).
10-References:
* Saudi national formulary book
*Lixy application.
* http://reference.medscape.com/
* http://www.webmd.com/
*http://www.Uptodate.com/
Norah fahad alfayez 436019528